Ma contribution critique au brouillon du rapport sur la vape du Comité Scientifique de l'UE (SCHEER)
Je partage ici seulement ma contribution sur le résumé court (abstract). J’ai également commenté d’autres parties du brouillon de rapport, sans être exhaustif. Les éléments du rapport étant assez répétitifs, je doute qu’il soit intéressant de lire l’ensemble, mais si vous voulez, demandez-moi par mail.
Quelques autres commentaires : Alistair a écrit une opinion pertinente à la sortie du brouillon du SCHEER sur Vaping Post ; Clive Bates a publié sur son blog une critique de fond, et son message au SCHEER ; et Christopher Snowdon a aussi commenté le sujet hier sur son blog.
*********************
We welcome SCHEER’s efforts to assess the topic of vaping in the context created by the TPD in the EU, prior to possible discussions on its revision. However this draft report fails to provide an adequate assessment in the European context on several points:
1) It does not make a relative risk assessment between vaping and cigarettes when almost all vaping users in the EU are or have been smokers (McNeill, 2018 ; Farsalinos 2016);
2) A large part of the studies cited concern products from outside the EU market; or, do not distinguish between uses with or without nicotine (or otherwise); and come from regulatory context radically different from that created by the TPD;
3) Some important European studies are not reviewed;
4) Another gap in relation to its mandate, the SCHEER draft never addresses the impact of regulations and/or actions of authorities on the issues addressed (Hua-Hie Yong, 2017 ; Ward, 2020).
It would have been desirable the Scientific Committee analysed risks produced by the different national implementations:
- evolution of smoking prevalence and evolution of the risks linked, between country tolerant to vaping, e.g. France, and country stigmatising vaping, e.g. Spain;
- the effects of ban flavours and high taxes, e.g. Estonia, and the risks associated with the creation of a vast black market out of control.
On the abstract text itself, we note:
[p. 2 l. 14] The data presented in the report do not seem to allow asserting strong evidence of systemic cardiovascular effects (Benowitz, 2016 ; Shahab, 2017).
[p.2 l.16] & [p.2 l.37] Data for products marketed under the TPD regime, which is the subject of this report, cannot support a carcinogenic risk by nitrosamine accumulation. Nicotine used in the EU is a highly purified grade (TPD art. 20 §3.d, 2014). This point indicates a more general confusion in the heterogeneous data used by the SCHEER, who does not seem to have discriminated the relevant data for specific European situation created by TPD.
[p. 2 l. 42 ss] The gateway hypothesis is not supported by the evidence presented in this report. The studies presented suffer from critical problems, including a lack of consideration of the risk co-factor of parental smoking and friends smoking, high attrition bias, etc. (Chan et al. 2020). The main meta-analysis presented has authors’ self-report bias. The scientific criteria for validating a causal hypothesis as the gateway theory are not met (Etter, 2017). More robust European studies, notably the OFDT study in France, show effects incompatible with this hypothesis (Chyderiotis, 2019). All this chapter and conclusion need to be completely revised.
[p. 2 l. 49 ss.] Many data were not included in the report. Cochrane review found 50 clinical studies and conclude to moderate-certainty evidence vaping with nicotine increase quit rate compared to NRT (Hartmann-Boyce, 2020). Preliminary results from other clinical studies (Eisenberg, ACC.20) are in the same direction. Santé Publique France has demonstrated that at least 700,000 people have quit smoking in a consolidated way thanks to vaping before 2017 (Pasquereau, 2017). Based on the Eurobarometer 429, an estimated 6 million EU citizens had quit with the help of vaping in 2014 (Farsalinos, 2016). The Smoking Toolkit Study showed that smoking cessation increased by ~70,000 net additional successful quitters thanks to vaping in 2017 in England (ASH, 2020). etc.
We recommend a thorough and rigorous revision of the draft report before its transmission to the Commission.
Les références de ce commentaire:
McNeill, A.,
Brose, L.S., Calder, R., Bauld, L. and Robson, D. (2018). Evidence review of
e-cigarettes and heated tobacco products. Public Health England, London, UK https://www.gov.uk/government/news/phe-publishes-independent-expert-e-cigarettes-evidence-review
Farsalinos, K. E., et al. (2016). "Electronic cigarette
use in the European Union: analysis of a representative sample of 27 460
Europeans from 28 countries." Addiction 111(11). https://onlinelibrary.wiley.com/doi/abs/10.1111/add.13506
Yong HH, Hitchman SC, Cummings KM, et al.
Does the Regulatory Environment for E-Cigarettes Influence the Effectiveness of
E-Cigarettes for Smoking Cessation?: Longitudinal Findings From the ITC Four
Country Survey. Nicotine Tob Res. 2017;19(11):1268-1276.
doi:10.1093/ntr/ntx056 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896424/
Ward
E, Anholt C, Gentry S, Dawkins L, Holland R, Notley C. A Qualitative Exploration
of Consumers’ Perceived Impacts, Behavioural Reactions, and Future Reflections
of the EU Tobacco Products Directive (2017) as Applied to Electronic
Cigarettes. Tobacco Use Insights. January 2020. doi:10.1177/1179173X20925458 https://journals.sagepub.com/doi/full/10.1177/1179173X20925458
Benowitz,
N. L., & Burbank, A. D. (2016). Cardiovascular toxicity of nicotine:
Implications for electronic cigarette use. Trends in cardiovascular medicine,
26(6), 515–523. https://doi.org/10.1016/j.tcm.2016.03.001
Shahab, L, Goniewicz, ML, Blount,
BC, Nicotine,
carcinogen, and toxin exposure in long-term e-cigarette and nicotine
replacement therapy users. Ann Intern Med. 2017;166:390-400. .
Gateway or
common liability? A systematic review and meta‐analysis of studies of
adolescent e‐cigarette use and future smoking initiation. Gary C. K. Chan Daniel Stjepanović Carmen Lim
Tianze Sun Aathavan Shanmuga
Anandan Jason P. Connor Coral Gartner
Wayne D. Hall Janni Leung - First
published: 04 September 2020 https://doi.org/10.1111/add.15246
Gateway
effects and electronic cigarettes, Jean‐François Etter, Addiction, vol. 113
issue 10, 2018 https://doi.org/10.1111/add.13924
Sandra
Chyderiotis, Tarik Benmarhnia, François Beck, Stanislas Spilka, Stéphane
Legleye, Does e-cigarette experimentation increase the transition to daily
smoking among young ever-smokers in France?, Drug and Alcohol Dependence,
Volume 208, 2020, https://doi.org/10.1016/j.drugalcdep.2020.107853.
Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Butler AR, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No.: CD010216. DOI: 10.1002/14651858.CD010216.pub4. https://www.cochrane.org/CD010216/TOBACCO_can-electronic-cigarettes-help-people-stop-smoking-and-do-they-have-any-unwanted-effects-when-used
E-cigarettes more effective than
counseling alone for smoking cessation, AMERICAN COLLEGE OF CARDIOLOGY, march 2020, https://www.eurekalert.org/pub_releases/2020-03/acoc-eme033020.php
Pasquereau A, Quatremère G, Guignard R, Andler R,
Verrier F, Pourchez J, Richard JB, Nguyen‑Thanh
V. Baromètre de Santé publique France 2017. Usage de la cigarette électronique,
tabagisme et opinions des 18‑75 ans. Saint‑Maurice
: Santé publique France, 2019. https://www.researchgate.net/publication/337542002_USAGE_DE_LA_CIGARETTE_ELECTRONIQUE_TABAGISME_ET_OPINIONS_DES_18-75_ANS_Barometre_de_Sante_publique_France_2017
Action on Smoking and Health (ASH) Use of e-cigarettes (vapes) amoong adults in Great Britain, 2020 https://ash.org.uk/wp-content/uploads/2020/10/Use-of-e-cigarettes-vapes-among-adults-in-Great-Britain-2020.pdf
Romain
Dusautoir, Gianni Zarcone, Marie Verriele, Guillaume Garçon, Isabelle Fronval,
Nicolas Beauval, Delphine Allorge, Véronique Riffault, Nadine Locoge, Jean-Marc
Lo-Guidice, Sébastien Anthérieu : Comparison of the chemical composition
of aerosols from heated tobacco products, electronic cigarettes and tobacco
cigarettes and their toxic impacts on the human bronchial epithelial BEAS-2B
cells, Journal of Hazardous Materials, Volume 401, 2021, https://doi.org/10.1016/j.jhazmat.2020.123417.
C'est bien qu'il y ait eu des contributions critiques mais évidemment c'est loin de suffire car le processus lui même est fortement biaisé et sous contrôle bureaucratique qui se fiche pas mal des gens qui ne sont pas de l'avis de leur commission. Les décisions sont prises par les politiques: c'est eux/elles qu'il faut convaincre et 'influencer', probablement une par une, de préférence par une approche personnalisée. Qui connaît une députée européenne, des assistants parlementaires, etc? A quand une enquête contre-rapport disponible dans différentes langues (pas seulement anglais) et largement diffusé? Combien de porte-paroles efficaces? etc. Bien entendu toujours merci pour ton énorme travail mais il en faut davantage avec une communication élargie et mieux organisée.
RépondreSupprimer